Physician profile
Philip Malinas
NPI 1700934825
$110,703.77
in general payments reported to CMS, 2019-2025
33 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $7,897 · 2021: $22K · 2022: $13K · 2023: $9,858 · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $9,803 · Travel and Lodging: $2,851 · Consulting Fee: $560 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,832.38 |
| Food and Beverage | $9,803.39 |
| Travel and Lodging | $2,851.45 |
| Consulting Fee | $560.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $33,769.36 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $23,769.38 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $15,499.15 | 2021-2025 | |
| Alkermes, INC. | $13,275.76 | 2019-2025 | Aristada, Lybalvi |
| Eisai INC. | $6,729.56 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $5,561.72 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $1,560.20 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,354.91 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $991.36 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $800.07 | 2019-2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $719.56 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $715.82 | 2019-2025 | Trintellix |
| Lundbeck LLC | $705.12 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neuronetics, INC. | $696.38 | 2019-2025 | Neurostar Tms Therapy System |
| Tris Pharma INC | $635.14 | 2019-2025 | Dyanavel Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $595.98 | 2021-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $439.50 | 2021-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $432.48 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $406.87 | 2023-2024 | Quviviq |
| Allergan, INC. | $363.45 | 2019-2020 | |
| Corium, LLC | $325.17 | 2022-2024 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $315.61 | 2019-2024 | Rejoyn |
| Indivior INC. | $246.28 | 2022-2024 | Perseris |
| Collegium Pharmaceutical, INC. | $200.86 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $128.32 | 2022-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.29 | 2022 | |
| Luye Pharma (USA) LTD. | $118.47 | 2025 | Erzofri Extended-Release |
| Avanir Pharmaceuticals, INC. | $60.72 | 2022 | |
| Alfasigma USA, INC. | $55.54 | 2020-2021 | |
| Bausch Health US, LLC | $53.65 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.76 | 2023 | Aplenzin |
| Pfizer INC. | $21.05 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Malinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.